Chemical Information
Antiviral agent ID	DrugRepV_7465
Antiviral agent name	beta-Methylene TAD
IUPAC Name	[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[(2~{R},3~{S},4~{R},5~{R})-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methyl]phosphinic acid
SMILES (canonical)	C1=C(N=C(S1)C2C(C(C(O2)COP(=O)(CP(=O)(O)OCC3C(C(C(O3)N4C=NC5=C4N=CN=C5N)O)O)O)O)O)C(=O)N
SMILES (isomeric)	C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C4N=CN=C5N)O)O)O)O)O)C(=O)N
Molecular Formula	C20H27N7O13P2S
Molecular Weight (g/mol)	667.48
InChl	InChI=1S/C20H27N7O13P2S/c21-16-10-18(24-4-23-16)27(5-25-10)20-14(31)12(29)9(40-20)2-38-42(35,36)6-41(33,34)37-1-8-11(28)13(30)15(39-8)19-26-7(3-43-19)17(22)32/h3-5,8-9,11-15,20,28-31H,1-2,6H2,(H2,22,32)(H,33,34)(H,35,36)(H2,21,23,24)/t8-,9-,11-,12-,13-,14-,15-,20-/m1/s1
Structural Information
Clinical Information
Biological Information
Secondary Indication	West Nile virus (WNV) NA Uganda strain B 956
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	Vero
Secondary Indication (Viral titer)	14 CCID50
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	6 days
Secondary Indication (Drug concentration)	>1000 μg/ml
Secondary Indication (Cell based assay)	NR assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC50 [ 50 % ]
Reference	Morrey JD, Smee DF, Sidwell RW, Tseng C..Identification of active antiviral compounds against a New York isolate of West Nile virus..Antiviral Res. 2002 Jul;55(1):107-16. PMID:12076755
Comment	The compounds 6-azauridine, 6-azauridine triacetate, cyclopententylcytosine (CPE-C), mycophenolic acid and pyrazofurin appeared to have the greatest activities against the New York isolate, followed by 2-thio-6-azauridine.